微信公众号
证券之星APP
| 报告期 | 净资产收益率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | -1.5% | -100% | -59.57% | 41/52 | 3.55% | 澳洋健康 | 34.16% | 行业排名> |
| 2024-06-30 | -0.94% | -1075% | -487.5% | 39/52 | 2.24% | 澳洋健康 | 30.56% | 行业排名> |
| 2024-03-31 | -0.16% | -45.45% | 89.19% | 36/52 | 1.22% | 澳洋健康 | 28.14% | 行业排名> |
| 2023-12-31 | -1.48% | 65.9% | -97.33% | 39/52 | 3.83% | 澳洋健康 | 39.54% | 行业排名> |
| 2023-09-30 | -0.75% | -15.38% | -837.5% | 43/52 | 6.78% | 澳洋健康 | 61.84% | 行业排名> |
| 2023-06-30 | -0.08% | 97.04% | 27.27% | 41/52 | 1.93% | 澳洋健康 | 48.34% | 行业排名> |
| 2023-03-31 | -0.11% | 84.72% | 97.47% | 38/52 | 2.55% | 澳洋健康 | 58.19% | 行业排名> |
| 2022-12-31 | -4.34% | 2.91% | -567.69% | 40/52 | -0.52% | *ST宜康 | 75.53% | 行业排名> |
| 2022-09-30 | -0.65% | 62.21% | 75.93% | 42/52 | 11.21% | 博腾股份 | 39.77% | 行业排名> |
| 2022-06-30 | -2.7% | -100% | -275% | 45/52 | 5.46% | 睿智医药 | 41.16% | 行业排名> |
| 2022-03-31 | -0.72% | 36.84% | 83.89% | 40/52 | 3.09% | 澳洋健康 | 51.68% | 行业排名> |
| 2021-12-31 | -4.47% | 61.3% | -159.88% | 41/52 | -6.4% | 澳洋健康 | 40.93% | 行业排名> |
| 2021-09-30 | -1.72% | 14.85% | -27.41% | 35/52 | 2.38% | 金域医学 | 43.58% | 行业排名> |
| 2021-06-30 | -1.35% | 32.5% | -18.42% | 43/52 | 2.32% | 金域医学 | 35.41% | 行业排名> |
| 2021-03-31 | -1.14% | 23.49% | 90.13% | 31/52 | 1.85% | 阳光诺和 | 26.2% | 行业排名> |
| 2020-12-31 | -11.55% | 66.5% | -471.78% | 46/52 | 10.94% | 金域医学 | 13.23% | 行业排名> |
| 2020-09-30 | -2.02% | -18.82% | -1% | 27/52 | 7.83% | 万邦医药 | 52.05% | 行业排名> |
| 2020-06-30 | -2% | -422.58% | -34.23% | 32/52 | 2.51% | 华大基因 | 48.52% | 行业排名> |
| 2020-03-31 | -1.49% | -260.22% | 95.68% | 26/52 | -0.22% | 华大基因 | 31.24% | 行业排名> |
| 2019-12-31 | -34.48% | -6044.83% | -1928.24% | 47/52 | 64.11% | 阳光诺和 | 13.99% | 行业排名> |
| 2019-09-30 | -1.7% | -151.2% | -374.19% | 29/52 | 10.46% | 南华生物 | 2848.07% | 行业排名> |
| 2019-06-30 | 0.62% | -67.2% | -33.33% | 26/52 | 5.56% | 南华生物 | 98.98% | 行业排名> |
| 2019-03-31 | 0.93% | -20.51% | 60.34% | 20/52 | 3.44% | 南华生物 | 82.46% | 行业排名> |
| 2018-12-31 | 0.58% | -80.54% | -82.53% | 39/52 | -0.5% | 南华生物 | 48.41% | 行业排名> |
| 2018-09-30 | 3.32% | 23.88% | 75.66% | 21/52 | 2.84% | 万邦医药 | 106.72% | 行业排名> |
| 2018-06-30 | 1.89% | -5.03% | 61.54% | 20/52 | 1.7% | 国际医学 | 46.66% | 行业排名> |
| 2018-03-31 | 1.17% | 72.06% | -60.74% | 20/52 | 0.49% | 普蕊斯 | 22.99% | 行业排名> |
| 2017-12-31 | 2.98% | -11.57% | 11.19% | 32/52 | 2.03% | 通策医疗 | 6.02% | 行业排名> |
| 2017-09-30 | 2.68% | -16.51% | 34.67% | 23/52 | 8.61% | 普蕊斯 | 58.68% | 行业排名> |
| 2017-06-30 | 1.99% | 14.37% | 192.65% | 22/52 | 58.64% | 爱尔眼科 | 20.87% | 行业排名> |
| 2017-03-31 | 0.68% | -28.42% | -79.82% | 18/52 | -5.59% | 南华生物 | 1666.98% | 行业排名> |
| 2016-12-31 | 3.37% | 150.37% | 4.98% | 25/52 | 19.64% | 爱尔眼科 | 5.19% | 行业排名> |
| 2016-09-30 | 3.21% | 190.42% | 84.48% | 14/52 | 5.93% | 南华生物 | 383.03% | 行业排名> |
| 2016-06-30 | 1.74% | 147.93% | 83.16% | 16/52 | 3.33% | *ST宜康 | 36.84% | 行业排名> |
| 2016-03-31 | 0.95% | 166.43% | 114.2% | 13/52 | 1.51% | 药石科技 | 24.53% | 行业排名> |
| 2015-12-31 | -6.69% | -48.67% | -88.45% | 28/52 | 22.23% | 南华生物 | 55.01% | 行业排名> |
| 2015-09-30 | -3.55% | -614.49% | 2.2% | 19/52 | 5.27% | *ST宜康 | 36.74% | 行业排名> |
| 2015-06-30 | -3.63% | -36200% | -153.85% | 18/52 | -30.81% | 南华生物 | 24.73% | 行业排名> |
| 2015-03-31 | -1.43% | -202.14% | 68.22% | 16/52 | -5.77% | 南华生物 | 400.84% | 行业排名> |
| 2014-12-31 | -4.5% | -216.88% | -752.17% | 20/52 | -13% | 金域医学 | 22.92% | 行业排名> |
| 2014-09-30 | 0.69% | -88.85% | 7000% | 13/52 | -106.33% | 迪安诊断 | 11.5% | 行业排名> |
| 2014-06-30 | -0.01% | -100.22% | -100.71% | 14/52 | -89.54% | 退市海医 | 6.75% | 行业排名> |
| 2014-03-31 | 1.4% | -36.65% | -63.64% | 9/52 | -7.99% | 国际医学 | 5.94% | 行业排名> |